United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy… byPallavi MadhirajuSeptember 20, 2024